NCT04341532Completed
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Pulmonary exacerbations (PEx) are key events that lead to a decline in health status among CF patients, with many never recovering to baseline health. With the advancement of new CFTR modulators and other therapies increasing the lifespan of those living with CF, it will become increasingly important to have better strategies to manage PEx in order to have better outcomes following treatment. PEx treatment decisions will need to take into consideration the increasing frequency of antimicrobial resistance bacteria and the need to treat multiple types of bacteria at once. The purpose of this study is to analyze sputum samples from CF subjects at the time of PEx in order to identify markers of antimicrobial resistant bacteria and see how those relate to treatment responses. CF patients will be recruited from patients followed by the Adult CF Program at National Jewish Health. Within 48 hours of admission to the hospital for treatment of a PEx, subjects will be enrolled and sputum will be collected. The sputum will be processed and analyzed for the presence of antimicrobial resistant bacteria. These results will be compared to clinical data, such as spirometry and frequency of hospitalizations.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 83 (actual)
- First submitted
- 2 Apr 2020
- Start date
- 20 Feb 2020
- Primary completion date
- 26 Jul 2023
- Lead sponsor
- National Jewish Health
- Diseases
- Cystic fibrosis
- NCT number
- NCT04341532
What you commit to
- Study type: Observational
- Participants enrolled: 83
- From 20 Feb 2020 to the primary completion date, 26 Jul 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The presence of a condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or the quality of the data
Other
- Subjects who are not colonized with Pseudomonas aeruginosa and/or Staphylococcus aureus
Who the study is looking for
- CF patients 18 years or older who are hospitalized for IV treatment of an acute PEx
- Chronically infected with Pseudomonas aeruginosa and/or Staphylococcus aureus
- Can produce sputum
- Can provide written consent
- Willing to comply with study procedure
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Jewish Health Coordinator of this site? Confirm its status | Denver | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.